CY2023020I1 - Συνθεσεις mycoplasma bovis - Google Patents

Συνθεσεις mycoplasma bovis

Info

Publication number
CY2023020I1
CY2023020I1 CY2023020C CY2023020C CY2023020I1 CY 2023020 I1 CY2023020 I1 CY 2023020I1 CY 2023020 C CY2023020 C CY 2023020C CY 2023020 C CY2023020 C CY 2023020C CY 2023020 I1 CY2023020 I1 CY 2023020I1
Authority
CY
Cyprus
Prior art keywords
compositions
mycoplasma bovis
bovis
mycoplasma
bovis compositions
Prior art date
Application number
CY2023020C
Other languages
English (en)
Other versions
CY2023020I2 (el
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CY2023020I2 publication Critical patent/CY2023020I2/el
Publication of CY2023020I1 publication Critical patent/CY2023020I1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/0241Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/35Mycoplasma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY2023020C 2015-08-14 2023-10-03 Συνθεσεις mycoplasma bovis CY2023020I1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562205125P 2015-08-14 2015-08-14
PCT/US2016/046572 WO2017030901A1 (en) 2015-08-14 2016-08-11 Mycoplasma bovis compositions

Publications (2)

Publication Number Publication Date
CY2023020I2 CY2023020I2 (el) 2024-02-16
CY2023020I1 true CY2023020I1 (el) 2024-02-16

Family

ID=56800367

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20221100762T CY1125699T1 (el) 2015-08-14 2022-12-02 Συνθεσεις mycoplasma bovis
CY2023020C CY2023020I1 (el) 2015-08-14 2023-10-03 Συνθεσεις mycoplasma bovis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20221100762T CY1125699T1 (el) 2015-08-14 2022-12-02 Συνθεσεις mycoplasma bovis

Country Status (23)

Country Link
US (2) US11389518B2 (el)
EP (2) EP4137152A1 (el)
JP (1) JP6675484B2 (el)
CN (3) CN108135989B (el)
AU (2) AU2016307935B2 (el)
BR (1) BR112018002919B1 (el)
CA (1) CA2995101A1 (el)
CY (2) CY1125699T1 (el)
DK (1) DK3334454T3 (el)
ES (1) ES2933623T3 (el)
FI (1) FI3334454T3 (el)
FR (1) FR23C1037I1 (el)
HK (1) HK1251478A1 (el)
HR (1) HRP20221440T1 (el)
HU (2) HUE060545T2 (el)
LT (1) LT3334454T (el)
MX (1) MX2018001841A (el)
NL (1) NL301244I2 (el)
PL (1) PL3334454T3 (el)
PT (1) PT3334454T (el)
SI (1) SI3334454T1 (el)
WO (1) WO2017030901A1 (el)
ZA (1) ZA201800956B (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109022314B (zh) * 2018-08-06 2021-08-13 北京华夏兴洋生物科技有限公司 一株牛支原体及其在疫苗研制中的应用
CN111471695A (zh) * 2020-05-11 2020-07-31 吉林农业大学 牛支原体免疫磁珠的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
JPH07507854A (ja) 1991-12-23 1995-08-31 ツォッヒェ,ミヒャエル 油除去装置を備えたエンジン
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE364090T1 (de) 1996-02-28 2007-06-15 Bayer Healthcare Ag Parapockenviren, die fremd-dna enthalten, ihre herstellung und ihre verwendung in impfstoffen
BR9712852A (pt) 1996-10-23 1999-11-16 Univ Pennsylvania Plasmìdeo, composição, processo de imunização de um indivìduo contra um patógeno, vacina recombinante, patógeno vivo atenuado, proteìna bl-1 substancialmente pura, vetor recombinante de expressão, e, anticorpo isolado
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
WO1999043839A1 (en) 1998-02-27 1999-09-02 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
KR100625385B1 (ko) 1998-03-13 2006-09-18 와이어쓰 폴리뉴클레오티드 조성물, 이의 제조방법, 및 용도
BR9914160A (pt) 1998-09-30 2001-06-26 American Cyanamid Co Composição antigênica, método para aumentar a capacidade de uma composição antigênica que contenha um antìgeno selecionado de uma bactéria, vìrus, fungo ou parasita patogênicos, do haemophilus influenzae, do helicobacter pylori, do vìrus sincicial respiratório, do rotavìrus, e, do vìrus simples do herpes para evocar a resposta imune de um hospedeiro vertebrado, plasmìdeo, célula hospedeira, método para produzir uma holotoxina do cólera mutante imunogênica, e, uso de uma quantidade auxiliar eficaz de uma holotoxina do cólera mutante
EP1229929A2 (en) 1999-11-08 2002-08-14 Biomune VACCINES FOR i MYCOPLASMA BOVIS /i AND METHODS OF USE
US6548069B2 (en) 2001-02-03 2003-04-15 Hmv Associates, Inc. Multivalent Mycoplasma bacterin
GB0110851D0 (en) 2001-05-03 2001-06-27 Mini Agriculture & Fisheries Vaccine
CN1541111A (zh) 2001-06-07 2004-10-27 ���Ͽع����޹�˾ 作为佐剂的霍乱全毒素的突变形式
EP1404368B1 (en) 2001-06-07 2009-12-09 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
US20030147914A1 (en) 2001-07-02 2003-08-07 Pfizer Inc. Mycoplasma bovis vaccine and methods of reducing pneumonia in animals
WO2005048957A2 (en) 2003-02-20 2005-06-02 Therion Biologics Corporation Novel insertion sites in pox vectors
US20090068231A1 (en) * 2007-09-11 2009-03-12 Wyeth Live attenuated mycoplasma strains
UY31437A1 (es) 2007-10-29 2009-05-29 Vacuna de mycoplasma bovis y métodos de uso de la misma
EP2320943B1 (en) 2008-07-03 2016-02-17 Iowa State University Research Foundation, Inc. Cattle vaccines
EP2362780B1 (en) 2008-10-31 2019-12-25 Boehringer Ingelheim Animal Health USA Inc. Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
MX2011007606A (es) * 2009-02-20 2011-08-08 Australian Poultry Crc Pty Ltd Vacunas atenuadas vivas.
UY32570A (es) 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada

Also Published As

Publication number Publication date
CN108135989B (zh) 2022-08-09
US11389518B2 (en) 2022-07-19
DK3334454T3 (da) 2022-11-14
HUS2300032I1 (hu) 2023-10-28
EP3334454B1 (en) 2022-10-19
US20220296694A1 (en) 2022-09-22
ES2933623T3 (es) 2023-02-10
CN115141772A (zh) 2022-10-04
CN115141773A (zh) 2022-10-04
CN108135989A (zh) 2018-06-08
AU2016307935B2 (en) 2022-08-18
LT3334454T (lt) 2022-12-27
EP3334454A1 (en) 2018-06-20
BR112018002919B1 (pt) 2024-02-27
HUE060545T2 (hu) 2023-03-28
WO2017030901A1 (en) 2017-02-23
FR23C1037I1 (fr) 2023-12-08
MX2018001841A (es) 2018-08-01
NL301244I1 (nl) 2023-10-04
HRP20221440T1 (hr) 2023-02-03
CA2995101A1 (en) 2017-02-23
AU2016307935A1 (en) 2018-02-22
JP2018523708A (ja) 2018-08-23
CY2023020I2 (el) 2024-02-16
PT3334454T (pt) 2022-12-20
PL3334454T3 (pl) 2023-01-30
US20190255166A1 (en) 2019-08-22
NL301244I2 (nl) 2023-11-01
JP6675484B2 (ja) 2020-04-01
CY1125699T1 (el) 2024-02-16
ZA201800956B (en) 2018-12-19
SI3334454T1 (sl) 2023-02-28
AU2022231761A1 (en) 2022-10-06
HK1251478A1 (zh) 2019-02-01
FI3334454T3 (fi) 2023-01-13
EP4137152A1 (en) 2023-02-22
BR112018002919A2 (pt) 2018-09-18

Similar Documents

Publication Publication Date Title
DK3361870T3 (da) Fungicidsammensætninger
DK3215173T3 (da) Glycopeptidsammensætninger
MA41976A (fr) Composition lubrifiante ultra-fluide
DK3040326T3 (da) Haloolefin-baseret sammensætning
DK3334726T3 (da) Plinabulinsammensætninger
FR3034100B1 (fr) Composition lubrifiante
DK3250182T3 (da) Dispergible sammensætninger
FR3024363B1 (fr) Composition thermogelifiable
DK3528902T3 (da) Ringegelsammensætning
CL2017000639A1 (es) Composición
DK3331498T3 (da) Nasalsammensætning
FR3020948B1 (fr) Composition antimicrobienne
CY2023020I1 (el) Συνθεσεις mycoplasma bovis
DK3316857T3 (da) Multifasiske sammensætninger
DK3393254T3 (da) Sammensætning
DK3200827T3 (da) Sammensætninger
DK3528791T3 (da) Dispergible sammensætninger
DK3416502T3 (da) Glykæmisk-reducerende sammensætning
DK3337322T3 (da) Fungicidsammensætninger
DK3317458T3 (da) Mineralsammensætninger
BR112017016240A2 (pt) composição
DK3217964T3 (da) Sammensætning
FR3025106B1 (fr) Composition antimicrobienne
FR3019552B1 (fr) Composition filmogene
DK3347444T3 (da) Fedtsammensætninger